Patents by Inventor Sundian Liu

Sundian Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240074990
    Abstract: The present invention relates to application of gossypol and its optical isomers to preparation of an anti-Coronavirus drug. Specifically disclosed is application of pharmaceutically acceptable salts, solvates, isotopes, stereoisomers, stereoisomer mixtures, and tautomers of the gossypol and its optical isomers to preparation of a drug for preventing and/or treating a disease caused by a Coronavirus. The Coronavirus is MERS-CoV, SARS-CoV, or SARS-CoV-2. It is found in the present invention for the first time that the gossypol and its optical isomers can inhibit the activity of Coronavirus 3CL proteases to achieve an anti-Coronavirus effect. The half maximal inhibitory concentrations of gossypol and (?)-gossypol to SARS-CoV proteases and SARS-CoV-2 3CL proteases are all lower than 10 ?M. The anti-Coronavirus 3CL protease effect is good. Therefore, the gossypol and its optical isomers have the potential for use in the preparation of a drug for preventing and/or treating novel Coronavirus infections.
    Type: Application
    Filed: March 18, 2023
    Publication date: March 7, 2024
    Inventors: Xiaolin XIE, Dezhu ZHANG, Zhao MA, Boyang LI, Xuhua ZHOU, Lei TIAN, Chengyuan LIANG, Taotao QIANG, Jingyi LI, Liang XIN, Shaojun ZHANG, Kangxiong WU, Xiuding YANG, Sundian LIU, Yuting LIU
  • Publication number: 20230391736
    Abstract: The present invention relates to the technical field of medicinal chemistry, and particularly to a method for preparing a 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione compound inhibiting coronavirus 3CL protease activity and use thereof. Specifically, a compound of Formula I, or a pharmaceutically acceptable salt, or an optical isomer, or an isotope-substituted form thereof is provided. The compound effectively inhibits the SARS-CoV-2 3CLpro activity, and is useful in the preparation of a SARS-CoV-2 3CLpro inhibitor to block the replication and transcription of SARS-CoV-2 viruses in patients. The compound prepared in the present invention has high in-vitro safety, and very good prospect of application in the preparation of SARS-CoV-2 3CLpro inhibitors and anti-SARS-CoV-2 drugs.
    Type: Application
    Filed: March 18, 2023
    Publication date: December 7, 2023
    Inventors: Xiaolin XIE, Dezhu Zhang, Zhao Ma, Boyang Li, Xuhua Zhou, Chengyuan Liang, Liang Xin, Lei Tian, Jingyi Li, Kangxiong Wu, Shaojun Zhang, Xiuding Yang, Sundian Liu, Yuting Liu
  • Patent number: 11612603
    Abstract: Disclosed is a compound of formula I, a pharmaceutically acceptable salt, or a tautomer thereof. formula I. R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, methyl group, tert-butyl group, methoxy group, difluoromethyl, trifluoromethyl, trifluoromethoxy, nitro, halogen, phenyl and aromatic heterocyclic; R5 is a hydrogen or halogen; and R6 is hydrogen, C1-4 alkane or C1-4 cycloalkane.
    Type: Grant
    Filed: July 17, 2022
    Date of Patent: March 28, 2023
    Assignee: SHAANXI PANLONG PHARMACEUTICAL CO., LTD.
    Inventors: Chengyuan Liang, Liang Xin, Lei Tian, Jingyi Li, Xiaolin Xie, Dezhu Zhang, Kangxiong Wu, Shaojun Zhang, Xiuding Yang, Sundian Liu, Yuting Liu, Zhao Ma, Xuhua Zhou